{
  "symbol": "BMY",
  "name": "Bristol Myers Squibb",
  "sector": "Health Care",
  "industry": "Pharmaceuticals",
  "date_added": "1957-03-04",
  "headquarters": "New York City, New York",
  "founded": "1989 (1887)",
  "market_cap": 96157.728768,
  "pe_ratio": 17.630634,
  "forward_pe": 6.7212086,
  "eps": 2.68,
  "revenue": 47636.000768,
  "profit_margin": 0.11376,
  "debt_to_equity": 293.85,
  "return_on_equity": 0.31986,
  "dividend_yield": 5.36,
  "current_price": 47.250099182128906,
  "year_high": 61.83539280362421,
  "year_low": 37.92499243543564,
  "price_change_1d": 0.44663746282413774,
  "price_change_1w": 0.7646143236670704,
  "price_change_1m": 0.06953621437480868,
  "description": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Emplic",
  "website": "https://www.bms.com",
  "employees": 34100,
  "exchange": "NYQ",
  "currency": "USD",
  "analyst_target_price": 57.09591,
  "recommendation": 2.66667,
  "number_of_analysts": 22,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 68.0,
    "target_low": 36.0,
    "target_mean": 57.09591,
    "target_median": 55.5
  },
  "last_updated": "2025-07-09T11:17:59.334346",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}